Evidence map›Paper›PMID 38022835›Full record

ArticleTherapeutic advances in psychopharmacology2023

A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults.

Shen He, Yimin Yu, Jingjing Huang, Jiahui Yin, Yajuan Niu, Yazhou Lu, Bin Wu, Maosheng Fang, Xue Wang, Zhiping Tao and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in psychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Shen HeDepartment of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yimin YuDepartment of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jingjing HuangDepartment of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiahui YinCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Yajuan NiuBeijing HuiLongGuan Hospital, Beijing, China.
Yazhou LuBeijing Anding Hospital, Capital Medical University, Beijing, China.
Bin WuXI'AN Mental Health Center, Shanxi, China.
Maosheng FangWuhan Mental Health Center, Hubei, China.
Xue WangWest China Hospital, Sichuan University, Sichuan, China.
Zhiping TaoBrain Hospital of Jilin Province, Jilin, China.
Lehua LiThe Second Xiangya Hospital of Central South University, Hunan, China.
Kan LiJiangxi Mental Hospital, Jiangxi, China.
Yan LiDepartment of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiujuan DingSuzhou YiHua Biomedical Technology Co., Ltd., Suzhou, China.
Yifeng ShenShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, People's Republic of China.
Huafang LiShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, People's Republic of China.ORCID https://orcid.org/0000-0003-2384-8998
Shanghai Jiao Tong University · CNBeijing HuiLongGuan Hospital · CNBrain Hospital of Jilin · CNCapital Medical University · CNCentral South University · CNJiangxi Mental Health Center · CNShandong University of Traditional Chinese Medicine · CNSichuan University · CNXian Mental Health Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Almost one-third of patients with major depressive disorder (MDD) do not respond to conventional antidepressants, and new treatments for MDD are urgently needed. Objectives: This phase IIb clinical trial was designed to evaluate the efficacy and safety of Anyu Peibo capsules in the treatment of adults with MDD. Design: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study. Methods: A total of 172 patients with MDD from nine study centers were randomized (1:1) to receive placebo ( Results: The mean baseline MADRS total scores were 29.20 and 29.72 in the Anyu Peibo ( Conclusion: Anyu Peibo capsules may have an effective and safe antidepressant effect, which warrants further research.

Indexed as

antidepressant treatmentAnyu Peibo capsuleclinical trialmajor depressive disorder

Identifiers

PMID38022835
PMCPMC10666694
OpenAlexW4388917850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.